Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma

Clinical Radiology

Volumn 66, Issue 4, 2011, Pages 322-328

  Park, S Y ^a   Kim, J H ^a   Yoon, H J ^a   Lee, I S ^a   Yoon, H K ^a   Kim, K P ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEMOGLOBINEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79952315920     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2010.11.002     Document Type: Article

References (28)

1. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-contol study. Gastroenterology 2005;128:620-6. (Pubitemid 40585364)
2. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-7. (Pubitemid 38230849)
3. Khan SA, Howard CT, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14. (Pubitemid 41416587)
4. Singal AG, Rakoski MO, Salgia R, et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther 2010;31:625-33.
5. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995;70:425-9.
6. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008;113:2119-28.
7. Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007;30:1156-65. (Pubitemid 350059808)
8. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005;16:353-61. (Pubitemid 40354852)
9. Gusani NJ, Balaa FK, Steel JL, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008;12:129-37.
10. Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006;2:509-14.
11. Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008;113:1614-22.
12. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25:978-86. (Pubitemid 350002864)
13. Falkson G, Maclntyre JM, Moertel CG, et al. Primary liver cancer: an eastern cooperative oncology group trial. Cancer 1984;54:970-7. (Pubitemid 14069808)
14. Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374-83. (Pubitemid 33029082)
15. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856-67. (Pubitemid 44646688)
16. Katyal S, Oliver JH, Peterson MS, et al. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000;175:1665-72.
17. Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270-7.
18. Park YS, Kim JH, Kim KW, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol 2009;64:779-85.
19. Kim JH, Yoon HK, Kim SY, et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009;29:1291-8.
20. Yoon HJ, Kim JH, Kim KA, et al. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol 2010;65:271-7.
21. Buijs M, Vossen JA, Frangakis C, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization - single-center experience. Radiology 2008;249:346-54.
22. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-23.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. Newguidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
24. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009;15:4240-62.
25. Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298-305.
26. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.
27. Lee GW, Kang JH, Kim HG, et al. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 2006;29:127-31. (Pubitemid 44270949)
28. Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111-8. (Pubitemid 39665463)